Literature DB >> 23095618

Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases.

François Cauchy1, Béatrice Aussilhou, Safi Dokmak, David Fuks, Sébastien Gaujoux, Olivier Farges, Sandrine Faivre, Daniel Lepillé, Jacques Belghiti.   

Abstract

OBJECTIVES: To determine short- and long-term outcomes of major hepatectomy in patients with downstaged colorectal liver metastases considered initially unresectable (IU).
BACKGROUND: Improvements in both surgical technique and efficacy of chemotherapy have increased the rate of resection for IU colorectal liver metastases. The outcome of these patients needs to be reassessed. PATIENTS AND METHODS: From 2000 to 2011, 257 patients underwent major hepatectomy for colorectal liver metastases. Of these, 87 (34%) IU patients required portal vein occlusion after chemotherapy downstaging. Patients requiring less than 12 cycles and 12 or more cycles of chemotherapy before resection were defined as fast responders and slow responders, respectively.
RESULTS: Compared with fast responders, slow responders had increased mortality (0% vs 19%, P = 0.003) and major morbidity rates (20% vs 55%, P < 0.001) despite almost identical tumor characteristics and similar procedures. In multivariate analysis, the only factor associated with increased major morbidity was the existence of a number of chemotherapy cycles of 12 or more (hazard ratio [HR]: 5.32, confidence interval [CI]: 1.69-16.7, P = 0.004). One-, 3-, and 5-year disease-free survival rates for the entire population were 48%, 17.5%, and 13%, respectively. Multivariate analysis found that slow responders (HR: 2.89, CI: 1.67-5.04, P < 0.001) and patients without adjuvant chemotherapy (HR: 2.38, CI: 1.33-4.35, P = 0.004) had a significantly decreased disease-free survival. All slow responders postoperatively recurred within 3 years.
CONCLUSIONS: Liver resection in slow responders, that is, IU patients requiring 12 or more chemotherapy cycles and portal vein occlusion to achieve resectability, is associated with poor short- and long-term outcomes. These patients would probably benefit from more conservative strategies.

Entities:  

Mesh:

Year:  2012        PMID: 23095618     DOI: 10.1097/SLA.0b013e3182738204

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  17 in total

Review 1.  A literature review of associating liver partition and portal vein ligation for staged hepatectomy (ALPPS): so far, so good.

Authors:  Martin de Santibañes; Luis Boccalatte; Eduardo de Santibañes
Journal:  Updates Surg       Date:  2016-10-20

2.  Optimizing unresectable colorectal liver metastases for surgery--no limits, any benefits?

Authors:  Tamara M H Gall; Adam E Frampton; Jonathan Krell; Long R Jiao
Journal:  J Gastrointest Surg       Date:  2013-04-17       Impact factor: 3.452

3.  The ALPPS approach: should we sacrifice basic therapeutic rules in the name of innovation?

Authors:  J Figueras; J Belghiti
Journal:  World J Surg       Date:  2014-06       Impact factor: 3.352

4.  Oncological strategies for locally advanced rectal cancer with synchronous liver metastases, interval strategy versus rectum first strategy: a comparison of short-term outcomes.

Authors:  H Salvador-Rosés; S López-Ben; M Casellas-Robert; P Planellas; N Gómez-Romeu; R Farrés; E Ramos; A Codina-Cazador; J Figueras
Journal:  Clin Transl Oncol       Date:  2017-12-22       Impact factor: 3.405

5.  Complex Surgical Strategies to Improve Resectability in Borderline-Resectable Disease.

Authors:  Motaz Qadan; Michael I D'Angelica
Journal:  Curr Colorectal Cancer Rep       Date:  2015-08-18

6.  The Impact of Advancing Age on Recurrence and Survival Following Major Hepatectomy for Colorectal Liver Metastases.

Authors:  Richard Bell; Sanjay Pandanaboyana; Saira Nisar; Vivek Upasani; Giles Toogood; J Peter Lodge; K Raj Prasad
Journal:  J Gastrointest Surg       Date:  2016-10-21       Impact factor: 3.452

Review 7.  Recent Advances in Chemotherapy and Surgery for Colorectal Liver Metastases.

Authors:  Guillaume Passot; Olivier Soubrane; Felice Giuliante; Giuseppe Zimmitti; Diane Goéré; Suguru Yamashita; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2016-11-29       Impact factor: 11.740

8.  Prognostic factors of hepatectomy in initially unresectable colorectal liver metastasis: Indication for conversion therapy.

Authors:  Hiroya Iida; Masaki Kaibori; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Masahiko Kinoshita; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  Mol Clin Oncol       Date:  2018-09-03

9.  Does "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease?

Authors:  K Kataoka; A Kanazawa; S Iwamoto; T Kato; A Nakajima; A Arimoto
Journal:  World J Surg       Date:  2014-04       Impact factor: 3.352

10.  2012 Liver resections in the 21st century: we are far from zero mortality.

Authors:  Safi Dokmak; Fadhel Samir Ftériche; René Borscheid; François Cauchy; Olivier Farges; Jacques Belghiti
Journal:  HPB (Oxford)       Date:  2013-03-06       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.